Market Place
Sourcing Support
Codexis Unveils Enzymatic RNAi Therapeutics Synthesis Data
14 Nov 2024 //
GLOBENEWSWIRE
AI Therapeutics Announces Name Change to OrphAI Therapeutics
28 Sep 2023 //
GLOBENEWSWIRE
AI Therapeutics Announces Initiation of a Pha2 Trial of LAM-001 for (PAH)
31 Aug 2023 //
GLOBENEWSWIRE
AI Therapeutics Announces Investigator Initiated Phase 2 Trial to Study LAM-001
18 Aug 2023 //
GLOBENEWSWIRE
AI Therapeutics Appoints David Scheer as Chairman of the Board of Directors
12 Jul 2023 //
GLOBENEWSWIRE
AI Therapeutics Announces Poster Presentation at the 2023 ATSIC
09 May 2023 //
GLOBENEWSWIRE
AI Therapeutics Announces Result from Phase 2a Biomarker-driven Trial of AIT-101
05 Apr 2023 //
GLOBENEWSWIRE
AI Therapeutics` narrowed ambitions for ALS drug pay off
05 Apr 2023 //
FIERCE BIOTECH
AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042
25 Apr 2022 //
GLOBENEWSWIRE
AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer
16 Feb 2022 //
GLOBENEWSWIRE
AI Therapeutics Initiates Phase II Clinical Trial of AIT-101 in ALS
13 Jan 2022 //
GLOBENEWSWIRE
Yale-backed study to test efficacy of AI-selected therapy in COVID-19
28 Jul 2020 //
PHARMAFILE
AI Therapeutics Announces Start of Phase II Trial of LAM-002A
27 Jul 2020 //
BUSINESSWIRE
AI Therapeutics Announces Start of Ph II Trial of LAM-002A (apilimod dimesylate)
27 Jul 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.